Nektar Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NKTR and other ETFs, options, and stocks.

About NKTR

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. 

CEO
Howard W. Robin
CEOHoward W. Robin
Employees
63
Employees63
Headquarters
San Francisco, California
HeadquartersSan Francisco, California
Founded
1990
Founded1990
Employees
63
Employees63

NKTR Key Statistics

Market cap
1.40B
Market cap1.40B
Price-Earnings ratio
-6.15
Price-Earnings ratio-6.15
Dividend yield
—
Dividend yield—
Average volume
2.20M
Average volume2.20M
High today
$42.38
High today$42.38
Low today
$40.38
Low today$40.38
Open price
$40.38
Open price$40.38
Volume
1.07M
Volume1.07M
52 Week high
$109.00
52 Week high$109.00
52 Week low
$33.40
52 Week low$33.40

Stock Snapshot

As of today, Nektar Therapeutics(NKTR) shares are valued at $41.17. The company's market cap stands at 1.4B, with a P/E ratio of -6.15.

During the trading session on 2026-10-10, Nektar Therapeutics(NKTR) shares reached a daily high of $42.38 and a low of $40.38. At a current price of $41.17, the stock is +2.0% higher than the low and still -2.9% under the high.

Trading activity shows a volume of 1.07M, compared to an average daily volume of 2.2M.

The stock's 52-week range extends from a low of $33.40 to a high of $109.00.

The stock's 52-week range extends from a low of $33.40 to a high of $109.00.

NKTR News

Simply Wall St 24h
Lawsuit Win Could Be A Game Changer For Nektar Therapeutics - Simply Wall Street

...

Lawsuit Win Could Be A Game Changer For Nektar Therapeutics - Simply Wall Street
Simply Wall St 2d
Is Nektar Therapeutics Cheap As Rezpegaldesleukin Data Supports Phase 3 Plans?

Nektar Therapeutics (NKTR) recently presented new long-term rezpegaldesleukin data to dermatology specialists at the EADV Congress in Vienna, highlighting susta...

Is Nektar Therapeutics Cheap As Rezpegaldesleukin Data Supports Phase 3 Plans?

Analyst ratings

77%

of 13 ratings
Buy
76.9%
Hold
23.1%
Sell
0%

People also own

Based on the portfolios of people who own NKTR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.